Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ZURA stock hub

Zura Bio Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ZURAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

454.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ZURA

In the news

Latest news · ZURA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-41

P25 -105.6P50 -46.5P75 -3.1

ROIC-27.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ZURA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

173

Groups with data

Currency

USD

Showing 173 of 173 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001855644
Company name	Zura Bio Limited
Country	United States
Country code	US
Cusip	G9TY5A101
Employees	40
Employees Change	10%
Employees Change Percent	33.33
Enterprise value	$228.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	KYG9TY5A1016
Last refreshed	2026-05-10
Market cap	$454.5M
Market cap category	Small-Cap
Price	$4.79
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	ZURA
Website	https://zurabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-23.35%
FCF yield	-16.01%
P/B ratio	2.1x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-106.1M
Net Income Growth Years	0%
Profit Per Employee	$-2.7M
ROA	-25.39
ROCE	-37.57
ROE	-40.96
ROIC	-27.66

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	289.79%
Cagr3y	-2.45%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$228.6M
Cash	$225.6M
Current Assets	$227M
Current Liabilities	$11.7M
Equity	$216.9M
Liabilities	$11.7M
Long Term Assets	$1.6M
Long Term Liabilities	$0
Net Cash	$225.6M
Net Cash By Market Cap	$49.64
Net Cash Growth	32.26%
Net Debt Equity	$-1.04
Tangible Book Value	$216.9M
Tangible Book Value Per Share	$2.29
WACC	4.74

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	19.33
Net Working Capital	$-10.3M
Quick ratio	19.21
Working Capital	$215.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-14.31%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	289.43%
200-day SMA	4.31
3Y total return	-7.17%
50-day SMA	5.85
50-day SMA vs 200-day SMA	50over200
All Time High	37.55
All Time High Change	-87.24%
All Time High Date	2023-03-24
All Time Low	0.97
All Time Low Change	393.81%
All Time Low Date	2025-04-04
ATR	0.4
Beta	0.09
Beta1y	-0.02
Beta2y	1.33
Ch YTD	-8.59
High	4.84
High52	7.44
High52 Date	2026-03-10
High52ch	-35.62%
Low	4.35
Low52	0.98
Low52 Date	2025-06-02
Low52ch	388.78%
Ma50ch	-18.06%
Premarket Change Percent	-2.2
Premarket Price	$4.44
Premarket Volume	4,028
Price vs 200-day SMA	11.21%
RSI	37.58
RSI Monthly	52.14
RSI Weekly	47.64
Sharpe ratio	1.71x
Sortino ratio	3.78
Total Return	-14.31%
Tr YTD	-8.59
Tr1m	-15.22%
Tr1w	-8.06%
Tr3m	-20.3%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$9.33
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.18
Operating Income	$-81.5M
Price target	$13
Price Target Change	$171
Price Target Change Top	$94.78

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	54,742,820%
Float Percent	57.7%
Shares Insiders	11.64%
Shares Institutions	36.78%
Shares Out	94,880,710
Shares Qo Q	18.36%
Shares Yo Y	14.31%
Short Float	11.24%
Short Ratio	9.75
Short Shares	6.49

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-86.4M
Average Volume	675,207.2x
Bv Per Share	2.29
CAPEX	$-77,000
Ch1m	-15.22
Ch1w	-8.06
Ch1y	289.4
Ch3m	-20.3
Ch3y	-7.17
Ch6m	30.52
Change	5.51%
Change From Open	8.37
Close	4.54
Days Gap	-2.64
Depreciation Amortization	56,000
Dollar Volume	5,047,496
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-81.5M
EBITDA	$-81.4M
EPS	$-1.07
F Score	2
FCF	$-72.8M
FCF EV Yield	-31.79x
FCF Per Share	$-0.77
Financing CF	127,777,000
Fiscal Year End	December
Founded	2,022
Investing CF	-77,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-19
Ma150	5.07
Ma150ch	-5.54%
Ma20	5.33
Ma20ch	-10.13%
Net CF	55,025,000
Next Earnings Date	2026-08-13
Open	4.42
Optionable	Yes
Position In Range	89.8
Post Close	4.79
Postmarket Change Percent	-3.34
Postmarket Price	$4.63
Ppne	125,000
Pre Close	4.54
Price Date	2026-05-08
Ptbv Ratio	2.1
Relative Volume	1.56x
Share Based Comp	13,696,000
Tr6m	30.52%
Us State	Nevada
Volume	1,053,757

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ZURA pay a dividend?

Capital-return profile for this ticker.

Performance

ZURA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ZURA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+36.8%

Float: +57.7% of shares outstanding

Insider ownership

+11.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ZURA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

37.6

Neutral momentum band

Price vs 200-day MA

+11.2%

50/200-day relationship not available

Beta (5Y)

0.09

Less volatile than the market

Sharpe ratio

1.71

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ZURA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ZURA stock rating?

Zura Bio Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ZURA analysis?

The full report lives at /stocks/ZURA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ZURA?

The latest report frames ZURA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ZURA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.